01/05/2015
CRATEX®
Or the symptomatic treatment of mental losses due to organic brain syndrome within the framework of a general therapeutic concept in case of progressive impairment or loss of mental capacities (dementia syndrome) having as major symptoms: Deficient memory, disturbances of concentration, depressive mood, dizziness, tinnitus and headache. The primary target group includes patients with demential syndrome in primary degenerative dementia, vascular dementia and mixed forms of both. Individual response to the treatment cannot be predicted. Prior to starting treatment with this preparation, clarification should be obtained as to whether the pathological symptoms encountered are not based on an underlying disease requiring a specific treatment.
Improvement of the pain-free walking distance in peripheral arterial occlusive disease in FONTAINE stage II (intermittent claudication) within the framework of physical therapeutic measures, in particular walking training.
Vertigo of vascular and involutional origin.
Supportive treatment in case of tinnitus of vascular and involutional origin.
Active ingredient:
Ginkgo biloba extract EGb 761®
Cratex® contains Schwabe’s unique and patented Ginkgo biloba extract EGb 761®. Since its launch in 1975 EGb 761® has been an outstanding success in numerous countries. In several countries including Germany it is approved for the treatment of dementia and for vascular disorders such as tinnitus, vertigo and peripheral arterial occlusive disease. EGb 761® is manufactured in a patented multi-stage process. One ton (1,000 kg) of the dried leaves yields only 20 kg of EGb 761®. During the production process, the concentrations of active principles are increased by a factor of up to 100. In addition, potentially harmful ingredients are eliminated from the final product.
Approved indication in Germany:
For the symptomatic treatment of mental losses due to organic brain syndrome within the framework of a general therapeutic concept in case of progressive impairment or loss of mental capacities (dementia syndrome) having as major symptoms: Deficient memory, disturbances of concentration, depressive mood, dizziness, tinnitus and headache. The primary target group includes patients with demential syndrome in primary degenerative dementia, vascular dementia and mixed forms of both. Individual response to the treatment cannot be predicted. Prior to starting treatment with this preparation, clarification should be obtained as to whether the pathological symptoms encountered are not based on an underlying disease requiring a specific treatment. Improvement of the pain-free walking distance in peripheral arterial occlusive disease in FONTAINE stage II (intermittent claudication) within the framework of physical therapeutic measures, in particular walking training.
Vertigo of vascular and involutional origin.
Supportive treatment in case of tinnitus of vascular and involutional origin.
Note: If conditions persist, are unclear or new, consult a doctor as diseases requiring medical clarification might be involved.
For information on precautions for use, side effects and contra-indications see the package leaflet or contact your doctor or pharmacist.
